Canada Life’s ImmunityBio IBRX Stock Holding History

Canada Life’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,052	Closed	-$27K	–	2604
2020 Q4	$27K	Buy	+2,052	New	+$19.7K	﹤0.01%	2486
2017 Q2	–	Sell	-11,036	Closed	-$39K	–	2543
2017 Q1	$39K	Hold	11,036	–	–	﹤0.01%	2361
2016 Q4	$63K	Buy	+11,036	New	+$73.6K	﹤0.01%	2259

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Canada Life's IBRX Position: Q1 2021 in Review

Canada Life sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 2,052 shares — an estimated $27K sold.

Canada Life first reported a position in IBRX in Q4 2016 and held it in 3 quarters. The position peaked at $63K in Q4 2016. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

Canada Life reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
Canada Life sold 2,052 ImmunityBio shares in Q1 2021, an estimated $27K.
Canada Life first reported a position in ImmunityBio in Q4 2016 and held it in 3 quarters.
Canada Life's ImmunityBio position peaked at $63K in Q4 2016.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Canada Life's 13F filing for Q1 2021, filed 17 May 2021.